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Objective: To describe how maintenance eculizumab sustains improved renal function in severe 
atypical hemolytic uremic syndrome (aHUS).
Case report: A previously described 50-year-old woman with aHUS had a remarkable 
recovery with eculizumab, which safely reversed profound neurologic damage and eliminated 
the need for dialysis. Her recovery has been sustained on long-term eculizumab treatment. 
She initially received eculizumab 900 mg weekly for four doses. On week 5 she commenced 
maintenance therapy starting at 1200 mg every 2 weeks. Due to nausea and vomiting at that 
dose, the   maintenance dosing was reduced to 600 mg weekly, beginning on dose seven. 
After receiving 600 mg weekly for nine doses, eculizumab was then reduced to 600 mg 
every 2 weeks, with continued improvement in renal function. This dosing is lower than the 
usual 1200 mg every 2 weeks described in the adult literature and used in current clinical 
trials of aHUS.
Conclusion: Six months after the initial diagnosis, our patient continues to have improved 
renal function on maintenance doses of eculizumab as low as 600 mg every 2 weeks.
Keywords: eculizumab, aHUS, thrombotic microangiopathy, atypical hemolytic uremic 
syndrome
Introduction
Atypical Hemolytic Uremic Syndrome (aHUS) involves congenital or acquired chronic 
systemic alternative complement pathway dysregulation. This causes reduced host cell 
protection, dysfunctional complement activation of platelets and endothelial cells, 
inflammation, and thrombotic microangiopathy.1,2 Terminal complement inhibition 
with eculizumab safely reversed our patient’s neurologic changes and eliminated the 
need for dialysis.
While the optimal duration and frequency of therapy remains to be determined 
(and varies in the literature), complete and sustained terminal complement inhibition 
has been considered necessary for adequate control of aHUS.3 Previous publications 
have indicated that long-term eculizumab therapy helps avoid aHUS relapse and 
maintenance therapy is used in current aHUS clinical trials.1–6
Eculizumab has been reported to be safe and effective in aHUS, a condition of 
chronic systemic uncontrolled complement activation.4–15 Eculizumab is a high-
affinity humanized monoclonal anti-C5 antibody that blocks terminal complement 
activity. Eculizumab binds to and blocks cleavage of the terminal complement protein 
C5 into its pro-inflammatory, prothrombotic, and lytic products: C5a and the cytotoxic Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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  membrane-attack complex C5b-9. Upstream components of 
complement, most notably C3b, are left intact.3,7,15,16
While eculizumab is not yet FDA approved for aHUS, 
this update describes how long term eculizumab maintains 
and improves renal function, despite being used at doses 
lower than currently used in clinical trials. This update also 
reports the results of our patient’s genetic and antibody tests, 
all of which were normal.
Case summary and update
A previously described 50-year-old Caucasian woman was 
transferred to our intensive care unit with sepsis, pancolitis, 
acute renal failure, and thrombocytopenia. Low complement 
levels were noted: C3 was 35 (83–184) mg/dL and C4 was 6 
(17–59) mg/dL. ADAMTS13 activity was adequate at 63%. 
Stool studies were all negative (including Escherichia coli 
0157:H7 and Clostridium difficile). She underwent colectomy 
and was confirmed to have scattered fibrin microthrombi 
on her bowel specimen. Her renal failure worsened and 
continuous venovenous hemodialysis was initiated. A rapid 
neurologic decline occurred after surgery. Severe renal 
failure, profound neurologic changes, severe hemolysis, 
thrombotic microangiopathy, and low complement levels 
were all suggestive of atypical hemolytic uremic syndrome 
(aHUS). By hospital day 5, there were occasional schisto-
cytes on the peripheral smear. Since aHUS is characterized 
by chronic systemic uncontrolled complement activation,2 
the anti-C5 monoclonal antibody eculizumab (900 mg IV) 
was administered on hospital day 6. It was continued weekly 
for four doses, followed by maintenance therapy that was 
gradually reduced.16
Because eculizumab increases the risk of Neisseria 
  meningitidis, the meningococcal vaccine was given prior to 
the first dose, and 14 days of ciprofloxacin was prescribed 
for meningococcal prophylaxis.16
Her renal recovery was remarkable with eculizumab and 
she has remained off dialysis with long-term eculizumab 
treatment. Our patient’s rapid and profound neurologic deteri-
oration resulted from significant thrombotic microangiopathy. 
MRI showed a right parietal lobe infarction (images shown in 
original paper). Despite thrombotic microangiopathic brain 
injury, she had a swift and complete neurologic recovery 
with eculizumab.
The initial dosing schema used for our patient is similar 
to that used in the clinical trials of eculizumab in aHUS, but 
maintenance therapy has gradually been reduced over time 
to a dose lower than what is used in the trials. Maintenance 
therapy, starting on week 5, was planned to be 1200 mg 
every 2 weeks, as in the trials; however, this dose was 
only continued for doses five and six.17–19 Due to nausea at 
the 1200 mg dose, the seventh dose was delayed by 1 day 
because the patient refused it, but then agreed to a reduced 
dose of 600 mg weekly. Her creatinine continued to improve 
despite the dose modification. She then remained on 600 mg 
weekly for nine doses with stable renal function. Her dose 
was subsequently reduced to 600 mg every 2 weeks and her 
improved renal function has been maintained despite the 
dose reduction. Additionally, her creatinine has continued to 
decrease on maintenance therapy with recent levels as low as 
1.64 mg/dL (normal 0.5–1.3 mg/dL), despite maintenance 
dosing reduced to 600 mg every 2 weeks. Figures 1–6 show 
treatment responses over time with respect to creatinine, C3, 
C4, LDH, haptoglobin, and platelets.
Discussion
Maintenance eculizumab
Several authors have described how long-term eculizumab 
therapy helps avoid aHUS relapse.1–6 Mache et al describe 
how aHUS relapsed after discontinuation of eculizumab 
and resulted anuric end stage renal disease.1 They describe 
another patient who experienced improvement in renal 
function, as well as normalization of platelets and hap-
toglobin, within 5 days of receiving eculizumab 600 mg. 
  Unfortunately, atypical hemolytic uremic syndrome relapsed 
2 weeks after recovery of complement-mediated hemolytic 
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Figure 1 serum creatinine levels as a function of time (days). 
Notes: Creatinine levels are marked with open red circles and the data points are 
connected with straight lines. For the purposes of reference, the normal creatinine 
range (0.5–1.3 mg/dL) is shown as open blue circles. The days corresponding to 
eculizumab administration are indicated by red asterisks along the horizontal time 
axis, appearing on days: 6, 13, 20, 27, 34, 48, 63, 70, 77, 84, 91, 98, 105, 112, 119, 133, 
146, 160, 174, 188, and 202. The start and end dates of dialyses administration are 
marked on the time axis of the figure by two blue open triangles, on days 4 and 26.Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
47
Maintenance eculizumab in atypical hemolytic uremic syndrome
activity,   suggesting the need for sustained complement 
inhibition to prevent relapse.
Châtelet et al described a transplant patient who was on 
a maintenance eculizumab 1200 mg every 14 days.2 They 
reported that a 6-day delay in administering the ninth dose 
resulted in recurrent hemolysis and deterioration of transplant 
function. The authors consequently resumed eculizumab as 
permanent therapy for their patient, with recovery of renal 
function. Similarly, in our patient, when the seventh dose was 
due, laboratory investigations suggested relapsing hemolysis, 
with haptoglobin ,6 mg/dL, indicating her continued need 
for the drug.
Zuber et al mention similar cases which emphasize the 
importance of long-term eculizumab therapy.3 They describe 
two post-transplant aHUS cases in which a single dose of 
eculizumab resulted in long-term remission in both patients. 
However, in both cases relapse ultimately occurred. Relapse 
occurred after 11.5 months for one patient and eculizumab was 
resumed, resulting in a remission. The other patient relapsed 
after 21 months, but when eculizumab was resumed, graft loss 
could be not prevented. Zuber et al suggest that a single dose of 
eculizumab is less effective than prolonged therapy and argue 
that the interval between doses be no more than 14 days.3
Genetic testing in aHUs
Approximately 60% of aHUS cases (familial and sporadic) 
have been associated with genetic mutations in complement 
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Figure 2 Lactate dehydrogenase as a function of time (days). 
Notes: Lactate dehydrogenase levels are marked with open red circles and the data 
points are connected with straight lines. For the purposes of reference, the normal 
range (108–202 U/L) is shown as open blue circles. Lactate dehydrogenase is shown 
as a function of time (days). Lactate dehydrogenase gradually dropped after initiating 
treatment with eculizumab. eculizumab administration is denoted by vertical tick 
marks (days 6, 13, 20, 27, 34, 48, 63, 70, 77, 84, 91, 98, 105, 112, 119, 133, 146, 160, 
174, 188, and 202). The start and end dates of dialyses administration are marked on 
the time axis of the figure by two blue open triangles, on days 4 and 26. Four days 
after the first dose, lactate dehydrogenase dropped to 837 U/L. After the second 
dose of eculizumab on day 13, lactate dehydrogenase dropped to 556 U/L. A week 
after the third dose, lactate dehydrogenase was down to 349 U/L. Three days after 
the sixth dose, lactate dehydrogenase was normal. It did rise slightly before the 
seventh dose was due.
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Figure 3 Haptoglobin as a function of time (days). 
Notes: Haptoglobin levels are marked with open red circles and the data points 
are connected with straight lines. For the purposes of reference, the normal range 
(62–197 mg/dL) is shown as open blue circles. eculizumab administration is denoted 
by vertical tick marks (days 6, 13, 20, 27, 34, 48, 63, 70, 77, 84, 91, 98, 105, 112, 
119, 133, 146, 160, 174, 188, and 202). Initial haptoglobin was ,6 mg/dL (normal 
range  62–197  mg/dL).  Five  days  after  the  third  dose,  haptoglobin  was  normal 
and remained normal until the time the seventh dose was due. Haptoglobin then 
dropped precipitously, indicating an ongoing need for the drug. Haptoglobin did 
increase again after the seventh dose on day 63, and later normalized to 71 mg/dL 
3 days after receiving the eighth dose on day 69. The start and end dates of dialyses 
administration are marked on the time axis of the figure by two blue open triangles, 
on the days 4 and 26.
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Figure 4 C3 as a function of time (days). 
Notes:  C3  levels  are  marked  with  open  red  circles  and  the  data  points  are 
connected with straight lines. For the purposes of reference, the normal range 
(83–184 mg/dL) is shown as open blue circles. C3 is shown as a function of time 
(days). eculizumab administration is denoted by vertical tick marks (days 6, 13, 20, 
27, 34, 48, 63, 70, 77, 84, 91, 98, 105, 112, 119, 133, 146, 160, 174, 188, and 202). 
The start and end dates of dialyses administration are marked on the time axis of 
the figure by two blue open triangles, on the days 4 and 26. After the second dose 
of eculizumab on day 13, C3 rose to 81. Thirteen days after the sixth dose, C3 was 
normal and remained normal.Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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regulatory proteins of the alternative complement pathway or 
auto-antibodies to the complement regulatory factor CFH.19,20 
Consequently, we ordered the following genetic and antibody 
tests for our patient: CFH, CFB, CFI, CFHR3-CFHR1 (deletion 
testing), MCP, THBD, C3, and CFH auto-antibodies (serum 
test). The Complement Hemolytic assay (serum test) was also 
ordered. All these results were normal for our patient.
As gene sequencing is very time consuming, it can take 
several months for all of the genetic tests to return. In the 
case of our patient, all of the results were available 6 months 
after they were ordered. Furthermore, very few clinical labo-
ratories do genetic testing for aHUS, but such labs may be 
found on the National Center for Biotechnology Information 
(NCBI) website: http://www.genetests.org/.21 Our patient’s 
genetic tests were performed at University of Iowa, which, 
to our knowledge, may be the only lab in the US that does 
these tests.22
Atypical HUS has been linked to the chromosome 1q32 
locus containing genes for complement factor H (CFH), the 
plasma regulator of the alternative complement pathway, as 
well as for other complement regulators. Over 80 CFH muta-
tions have been identified in aHUS patients. In familial aHUS 
the frequency of CFH mutations is 40%–50%. In the sporadic 
form, the frequency of CFH mutations is 20%.19,20 The various 
genetic abnormalities and antibody abnormalities currently 
identified in aHUS are summarized below. More information 
on genetic mutations in aHUS can be obtained from two 
comprehensive papers by Noris and Remuzzi.19,20
•	 CFH regulates the alternative complement pathway (AP). 
In aHUS, most CFH mutations are heterozygous.19,20 
Mutant CFH heterozygotes usually carry normal levels 
of CFH but 50% of the molecules are dysfunctional. Only 
15%–20% of CFH mutations in aHUS are homozygous, 
resulting in quantitative CFH deficiency and very low C3 
levels. 19,20
•	 3%–5% of aHUS cases possess a heterozygous hybrid 
gene. The hybrid gene results from aberrant crossover 
between CFH and CFHR1, a gene located in tandem 
to CFH. CFHR1 encodes complement factor H related 
protein (CFHR1). The gene product has decreased 
endothelial complement regulatory activity.19,20
•	 Deletion testing for CFHR1 and CFHR3 was ordered 
because these gene deletions are considered a risk factor 
for aHUS.23
•	 Approximately 6%–10% of aHUS patients acquire anti-
CFH antibodies, which emulate CFH mutations by bind-
ing to the CFH C-terminus and decreasing CFH binding 
to C3b and surface cofactor activity.19,20 Furthermore, 
some aHUS patients acquire autoantibodies to Factor H 
in the setting of deletions of CFHR1 and CFHR3.24
•	 CFI is a plasma serine protease that regulates all three 
complement pathways by cleaving C3b and C4b. 
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Figure 6 Platelets as a function of time (days). 
Notes: Platelet levels are marked with open red circles and the data points are connected 
with straight lines. For the purposes of reference, the normal range (150–450 × 109/L) is 
shown as open blue circles. The days corresponding to eculizumab administration are 
indicated by red asterisks along the horizontal time axis, appearing on days: 6, 13, 20, 
27, 34, 48, 63, 70, 77, 84, 91, 98, 105, 112, 119, 133, 146, 160, 174, 188, and 202. On 
the day of transfer, hospital day 1, the patient underwent total abdominal colectomy. 
During surgery, she received 2U of pooled platelets. Initial platelets before surgery 
were 28 × 109/L. After surgery, her platelets rose, and continued to rise during the 
first 5 days of the admission, without additional transfusions. The rising platelets after 
colectomy suggested previous platelet consumption by a thrombotic microangiopathic 
process in the colon. After initiating eculizumab, her platelets continued to rise.
02 04 06 08 0 100 120 140 160 180 200
0
10
20
30
40
50
60
70
Time in days
C
4
 
C
o
m
p
l
e
m
e
n
t
 
v
a
l
u
e
s
 
(
m
g
/
d
L
)
Figure 5 C4 as a function of time (days). 
Notes: C4 levels are marked with open red circles and the data points are connected 
with straight lines. For the purposes of reference, the normal range (17 to 59 mg/dL) 
is shown as open blue circles. C4 is shown as a function of time (days). eculizumab 
administration is denoted by vertical tick marks (days 6, 13, 20, 27, 34, 48, 63, 70, 
77, 84, 91, 98, 105, 112, 119, 133, 146, 160, 174, 188, and 202). The start and end 
dates of dialyses administration are marked on the time axis of the figure by two 
blue open triangles, on days 4 and 26. The day after the second dose of eculizumab 
on day 13, C4 rose to 16. Three days after the sixth dose, C4 was normal and 
remained normal.Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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4%–10% of aHUS cases involve a heterozygously 
mutated CFI. 19,20 As a proteolytic enzyme, CFI prevents 
hemolytic and immune-adherence activities of activated, 
cell-bound C3.22
•	 MCP encodes the membrane cofactor protein (MCP), 
which is a cofactor for CFI to cleave C3b and C4b on 
cell surfaces. Around 10% of aHUS cases involve MCP 
mutations, the majority of which are heterozygous.19,20
•	 Some patients have gain of function mutations that 
affect genes encoding CFB and C3, which are the AP 
C3 convertase components. CFB mutations, accounting 
for only 1%–2% of aHUS cases, result in chronic AP 
activation with low C3 level and normal C4 levels.19,20 
Approximately 4%–10% of aHUS cases have heterozy-
gously mutated C3, associated with reduced C3b binding 
to CFH and MCP, significantly hindering degradation of 
mutant C3b and resulting in low C3 levels.19,20
•	 Around 5% of aHUS patients have heterozygously mutated 
THBD, resulting in inefficient inactivation of C3b. THBD 
encodes thrombomodulin that is involved in   complement 
activation on cell surfaces.19,20   Thrombomodulin is 
  actually a negative regulator of the complement system, 
which suppresses leukocyte   trafficking, inflammation, 
and complement activation.22,25
•	 Of note, 3%–5% of aHUS patients possess combined 
mutations, often in CFH along with either MCP or CFI. 
Few also possess anti-CFH antibodies.19,20
Although genetic testing did not change the management 
of our patient, genetic testing in aHUS can provide the clini-
cian with information about disease process and long-term 
renal transplant outcome.19,20 For example, mutations of CFH, 
CFI, CFB, and C3 have been associated with post-transplant 
recurrence. This is due to the fact that the mutations give rise 
to abnormalities in circulating proteins that mostly come from 
the liver, and thus can exist even after kidney transplant.19,20
Conclusion
Six months after initial diagnosis, our patient continues 
to have improved renal function on maintenance doses of 
eculizumab as low as 600 mg every 2 weeks. This dose is 
much lower than what is used in the current clinical trials, 
suggesting that complement inhibition needs vary among 
patients. Clinical trials are underway to determine the optimal 
dosing schema.
Although genetic abnormalities in complement regula-
tory factors or anti-CFH antibodies have been identified 
in approximately 60% of cases,19,20 genetic testing did not 
change the management of this patient.
Acknowledgment
The authors would like to acknowledge Camille Bedrosian, 
MD, for her important recommendations on the treatment 
of aHUS.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V , et al. Complement 
inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am 
Soc Nephrol. 2009;4(8):1312–1316.
  2.  Châtelet V , Lobbedez T, Frémeaux-Bacchi V , Ficheux M, Ryckelynck JP, 
Hurault de LB. Eculizumab: safety and efficacy after 17 months of 
treatment in a renal transplant patient with recurrent atypical hemo-
lytic-uremic syndrome: case report. Transplant Proc. 2010;42(10): 
4353–4355.
  3.  Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux-Bacchi V , 
Legendre C. New insights into postrenal transplant hemolytic uremic 
syndrome. Nat Rev Nephrol. 2011;7(1):23–35.
  4.  Nurnberger J, Phillip T, Witzke O, et al. Eculizumab for atypical 
hemolytic-uremic syndrome. N Engl J Med. 2009;360(5):542–544.
  5.  Châtelet V , Frémeaux-Bacchi V , Lobbedez T, Ficheux M, Hurault de LB. 
Safety and long-term efficacy of eculizumab in a renal transplant patient 
with recurrent atypical hemolytic-uremic syndrome. Am J Transplant. 
2009;9(11):2644–2645.
  6.  Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-
uremic syndrome. N Engl J Med. 2009;360(5):544–546.
  7.  Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. 
  Maintenance of kidney function following treatment with eculizumab 
and discontinuation of plasma exchange after a third kidney trans-
plant for atypical hemolytic uremic syndrome associated with a CFH 
  mutation. Am J Kidney Dis. 2010;55(44):708–711.
  8.  Zimmerhackl LB, Hofer J, Cortina G, et al. Prophylactic eculizumab 
after renal transplantation in atypical hemolytic-uremic syndrome. 
N Engl J Med. 2010;362(18):1746–1748.
  9.  Ardissino G, Testa S, Paglialonga F, et al. Remission of plasma-resistant 
atypical hemolytic uremic syndrome relapse on kidney graft with 
eculizumab. Presented at the 2nd International Conference on HUS-
MPGN-PNH; June 13–15, 2010; Innsbruck, Austria. p. 17.
  10.  Haffner H, Hofer J, Zimmerhackl LB, Pohl M. Effective eculizumab 
therapy of familiar atypical HUS in a 4 year old patient. Presented at 
the 2nd International Conference on HUS-MPGN-PNH; 2010 June 
13–15; Innsbruck, Austria. p. 21.
  11.  Lapayraque AL, Phan V , Clermont MJ, et al. Effectiveness of eculi-
zumab in a plasma infusion dependent patient with atypical haemolytic 
and uremic syndrome (a HUS) associated with heterozygous combined 
de Novo mutation in factor H gene. Presented at the 2nd International 
Conference on HUS-MPGN-PNH; June 13–15, 2010; Innsbruck, 
  Austria. p. 24.
  12.  Tschumi S, Bucher BS, Sparta G, et al. Eculizumab in atypical hemolytic 
uremic syndrome: long-term clinical course and histological findings. 
Presented at the 2nd International Conference on HUS-MPGN-PNH; 
June 13–15, 2010; Innsbruck, Austria. p. 44.
  13.  Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, 
Lozano M. Efficacy of eculizumab in the treatment of recurrent atypical 
hemolytic-uremic syndrome after renal transplantation.   Transplantation. 
2010;89(7):903–904.
  14.  Legault DJ, Boelkins MR. Successful treatment of aHUS recurrence 
and arrest of plasma exchange resistant TMA post-renal transplanta-
tion with the terminal complement inhibitor eculizumab. Presented at 
the 51st ASH Annual meeting; December 6, 2009; Grand Rapids, MI.   
p. 2421.Clinical Pharmacology: Advances and Applications
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-pharmacology-advances-and-applications-journal
Clinical Pharmacology: Advances and Applications is an international, 
peer-reviewed, open access journal publishing original research, reports, 
reviews and commentaries on all areas of drug experience in humans. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use.   
Visit http://www.dovepress.com/testimonials.php to read real quotes 
from published authors.
Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
50
Ohanian et al
  15.  Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R. 
FDA report: eculizumab (Soliris) for the treatment of patients with parox-
ysmal nocturnal hemoglobinuria. Oncologist. 2008;13(9):993–1000.
  16.  Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic 
impairment and eliminates need for dialysis in severe atypical hemolytic 
uremic syndrome. Clinical Pharmacology: Advances and Applications. 
doi: 10.2147/CPAA.S17904.
  17.  Alexion Pharmaceuticals. Open Label Controlled Trial of Eculizumab in 
Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Ure-
mic Syndrome (aHUS). In: ClinicalTrials.gov [Internet]. Bethesda, MD: 
National Library of Medicine (US). 2009. Available from: http://www.clin-
icaltrials.gov/ct2/show/NCT00838513?term=NCT00838513&rank=1.   
Accessed on October 5, 2011. NLM identifier: NCT00838513.
  18.  Muus P, Legendre C, Douglas K, Hourmant M, Delmas Y, Herthelius B, 
et al. Safety and Efficacy of Eculizumab in aHUS Patients on Chronic 
Plasma Therapy: Interim Analysis from a Phase II Trial [abstract]. 
Presented at American Society of Nephrology Meeting, Renal Week 
2010, Denver, CO. Available at: http://www.abstracts2view.com/asn10/
view.php?nu=ASN10L1_1338a. Accessed on October 5, 2011.
  19.  Noris M, Remuzzi G. Genetics and genetic testing in hemolytic   uremic 
syndrome/thrombotic thrombocytopenic purpura. Semin Nephrol. 2010; 
30(4):395–408.
  20.  Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J 
Med. 2009;361(17):1676–1687.
  21.  GeneTests [homepage]. Available at: http://www.ncbi.nlm.nih.gov/
sites/GeneTests. Accessed on October 5, 2011.
  22.  Molecular Otolaryngology and Renal Research Laboratories   [homepage]. 
Available at: http://www.healthcare.uiowa.edu/labs/morl/THBD.htm. 
Accessed on October 5, 2011.
  23.  Zipfel PF, Edey M, Heinen S, et al. Deletion of complement factor 
H-related genes CFHR1 and CFHR3 is associated with atypical hemo-
lytic uremic syndrome. PLoS Genet. 2007;3(3):e41.
  24.  Skerka C, Józsi M, Zipfel PF, Dragon-Durey MA, Frémeaux-Bacchi V . 
Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb 
  Haemost. 2009;101(2):227–232.
  25.  Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations 
in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(4): 
345–357.